



Press release

SHL Telemedicine signs a distribution agreement for the smartheart™ device with FUJIFILM Sonosite for the U.S., Japan and Germany.

Tel Aviv/Zurich, 7 May, 2015 - SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN), a leading provider and developer of advanced personal telemedicine solutions, today announced it has signed an international distribution agreement for its innovative smartheart™ device with FUJIFILM SonoSite, Inc.

smartheart™ is the first and only personal mobile 12-lead ECG device on the market that enables the detection of heart attacks. FUJIFILM SonoSite will distribute the smartheart™ device to its professional healthcare customers in the US, Japan and Germany, using its point-of-care ultrasound solutions. With smartheart and a smartphone or tablet they can perform a full hospital grade ECG and send it to a clinic, a hospital or SHL's telemedicine center for diagnosis.

FUJIFILM SonoSite, Inc. is a world leader in bedside and point-of-care ultrasound, and an industry leader in ultra high-frequency micro-ultrasound technology. Headquartered near Seattle (Washington, U.S.), the company is represented by 26 subsidiaries and a global distribution network in over 100 countries. SonoSite's portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care.

For more information please visit www.sonosite.com.

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. The Company operates in Israel, Germany, India and the United States in one business segment, Telemedicine services. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information please visit our web site at www.shl-telemedicine.com.

For further information please contact:

- Erez Alroy, Co-CEO, Phone: +972 3561 22 12, ereza@shl-telemedicine.com
- Martin Meier-Pfister, IRF Communications, Phone: +41 43 244 81 40, shl@irfcom.ch
- Garth Russell / Elizabeth Barker, U.S.A., Phone : +1 212-682-6300, grussell@kcsa.com / ebarker@kcsa.com



Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.